INTERACTION BETWEEN PHENCYCLIDINE (PCP) AND GABA-ERGIC DRUGS - CLINICAL IMPLICATIONS

被引：0

作者：

MENON, MK ^{[1
]}

CLARK, WG ^{[1
]}

VIVONIA, C ^{[1
]}

机构：

[1] UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT,LOS ANGELES,CA 90024

来源：

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR | 1980年 / 12卷 / 01期

关键词：

D O I：

暂无

中图分类号：

B84 [心理学]; C [社会科学总论]; Q98 [人类学];

学科分类号：

03 ; 0303 ; 030303 ; 04 ; 0402 ;

摘要：

引用

页码：113 / 117

页数：5

共 50 条

[1] IMPLICATIONS OF GABA-ERGIC SYNAPSES IN NEUROPSYCHIATRY
LLOYD, KG
PERRAULT, G
ZIVKOVIC, B
JOURNAL DE PHARMACOLOGIE, 1985, 16 : 5 - 27
[2] DOPAMINERGIC GABA-ERGIC INTERACTION IN THE NIGROSTRIATAL SYSTEM
KOLTAI, MZ
GYORGY, L
ACTA PHYSIOLOGICA ACADEMIAE SCIENTIARUM HUNGARICAE, 1981, 58 (03): : 225 - 233
[3] Interaction between the Dopaminergic and GABA-ergic Systems of the Cortex during Conditioning
N. M. Rozumna
Neurophysiology, 2002, 34 : 213 - 215
[4] THERAPEUTIC ACTIVITY OF POTENTIALLY GABA-ERGIC DRUGS IN NEUROPSYCHIATRY
BARTHOLINI, G
SCHWEIZER ARCHIV FUR NEUROLOGIE UND PSYCHIATRIE, 1979, 125 (02): : 265 - 269
[5] Interaction between the Dopaminergic and GABA-ergic Systems of the Cortex during Conditioning
Rozumna, N. M.
NEUROPHYSIOLOGY, 2002, 34 (2-3) : 213 - 215
[6] GABA-ERGIC DRUGS - EFFECTS ON CONDITIONING, MEMORY AND LEARNING
RAYEVSKY, KS
KHARLAMOV, AN
PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 1983, 15 (01): : 85 - 96
[7] Critical review of GABA-ergic drugs in the treatment of schizophrenia
Wassef, AA
Dott, SG
Harris, A
Brown, A
O'Boyle, M
Meyer, WJ
Rose, RM
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (03) : 222 - 232
[8] GABA-ergic mechanisms of cerebrovascular effects of novel neuroprotective drugs
Mirzo, RS
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S240 - S240
[9] MECHANISM OF TOLERANCE DEVELOPMENT TO PHENCYCLIDINE IN RELATION TO GABA-ERGIC NEURONAL AND DISPOSITIONAL FUNCTIONS IN MICE
NABESHIMA, T
KAMEYAMA, T
HO, IK
JOURNAL OF PHARMACOBIO-DYNAMICS, 1982, 5 (03): : S46 - S46
[10] GABA-ergic drugs: exit stage left, enter stage right
Ashton, H
Young, AH
JOURNAL OF PSYCHOPHARMACOLOGY, 2003, 17 (02) : 174 - 178

← 1 2 3 4 5 →